AI-based rare disease diagnostic company 3billion (CEO Changwon Geum) will participate in the '2026 American College of Clinical Genetics (ACMG) Annual Conference' held in Baltimore, Maryland, USA until March 14th.
ACMG is an international academic organization that brings together genetic medicine experts, researchers, and academics in the field of genetic diagnosis and treatment from around the world to share cutting-edge research and clinical standards. It holds a high level of authority in the field of genetics. At this event, 3billion will operate a dedicated booth to introduce its SaaS-based genetic mutation analysis platform, "GEBRA," and aim to raise global brand awareness.
Currently, 3billion provides whole-exome (WES) and whole-genome (WGS) genetic diagnostic services for rare diseases to medical institutions in 75 countries worldwide. Last year, its revenue more than doubled year-over-year, solidifying its position in the global market. Since its debut at ACMG last year, GEBRA has been adopted and utilized by medical professionals and researchers in over 20 countries.
During the conference, 3billion will demonstrate GEBRA's enhanced variant interpretation capabilities, demonstrating its ability to quickly and accurately analyze large-scale genomic data in a global diagnostic environment. GEBRA, a solution that uses AI to analyze millions of genetic variants per patient in real time and recommend diagnostic priorities, is recognized as a SaaS platform that can enhance diagnostic efficiency even in situations with a shortage of specialized personnel.
“ACMG is a gathering of key experts in the field of genetics, so it is an opportunity to promote GEBRA technology and strengthen our global network,” said Geum Chang-won, CEO of 3billion. “We will expand our AI genetic diagnosis platform business by utilizing our existing global network based on diagnostic services, and strengthen our technological leadership in the field of rare disease diagnosis.”
Meanwhile, during the conference, 3billion plans to expand its network with major North American medical institutions and researchers and focus on strengthening its presence in the local market.
- See more related articles
You must be logged in to post a comment.